bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S6 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

KM analyses by HPV- and cT, DeepPET-OPSCC risk category, entire cohort
Figure S4 from Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection
Authors: Jolissaint Joshua S. , Soares Kevin C. , Seier Kenneth P. , Kundra Ritika , Gönen Mithat , Shin Paul J. , Boerner Thomas , Sigel Carlie , Madupuri Ramyasree , Vakiani Efsevia , Cercek Andrea , Harding James J. , Kemeny Nancy E. , Connell Louise C. , Balachandran Vinod P. , D'Angelica Michael I. , Drebin Jeffrey A. , Kingham T. Peter , Wei Alice C. , Jarnagin William R.
Published: April 2023

Figure S4
Supplementary Table 3 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Authors: Bockorny Bruno , Macarulla Teresa , Semenisty Valerya , Borazanci Erkut , Feliu Jaime , Ponz-Sarvise Mariano , Abad David Gutierrez , Oberstein Paul , Alistar Angela , Muñoz Andres , Geva Ravit , Guillén-Ponce Carmen , Fernandez Mercedes Salgado , Peled Amnon , Chaney Marya , Gliko-Kabir Irit , Shemesh-Darvish Liron , Ickowicz Debby , Sorani Ella , Kadosh Shaul , Vainstein-Haras Abi , Hidalgo Manuel
Published: April 2023

Supplementary Table 3
Supplementary Figure 1 from Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study
Authors: Forsythe Steven D. , Erali Richard A. , Sasikumar Shyama , Laney Preston , Shelkey Ethan , D'Agostino Ralph , Miller Lance D. , Shen Perry , Levine Edward A. , Soker Shay , Votanopoulos Konstantinos I.
Published: April 2023

Flow cytometry analysis of CD8+ T-cells after co-culture with tumor cells in organoids for 1 week.
Supplementary Figure S1 from Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer
Authors: Loree Jonathan M. , Wang Yucai , Syed Muddassir A. , Sorokin Alexey V. , Coker Oluwadara , Xiu Joanne , Weinberg Benjamin A. , Vanderwalde Ari M. , Tesfaye Anteneh , Raymond Victoria M. , Miron Benjamin , Tarcic Gabi , Zelichov Ori , Broaddus Russell R. , Ng Patrick Kwok Shing , Jeong Kang Jin , Tsang Yiu Huen , Mills Gordon B. , Overman Michael J. , Grothey Axel , Marshall John L. , Kopetz Scott
Published: April 2023

Histogram demonstrating distribution of (A) RAS, (B) KRAS, and (C) NRAS mutations across clinical cohorts with survival data based on activity level.
Supplementary text from Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET
Authors: Garcia-Moure Marc , Gonzalez-Huarriz Marisol , Labiano Sara , Guruceaga Elizabeth , Bandres Eva , Zalacain Marta , Marrodan Lucia , de Andrea Carlos , Villalba Maria , Martinez-Velez Naiara , Laspidea Virginia , Puigdelloses Montse , Gallego Perez-Larraya Jaime , Iñigo-Marco Ignacio , Stripecke Renata , Chan Jennifer A. , Raabe Eric H. , Kool Marcel , Gomez-Manzano Candelaria , Fueyo Juan , Patiño-García Ana , Alonso Marta M.
Published: April 2023

Suplementary materials and figure legends for supplementary figures
Supplementary Data Legends from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Authors: Shoushtari Alexander N. , Chatila Walid K. , Arora Arshi , Sanchez-Vega Francisco , Kantheti Havish S. , Rojas Zamalloa Jorge A. , Krieger Penina , Callahan Margaret K. , Betof Warner Allison , Postow Michael A. , Momtaz Parisa , Nair Suresh , Ariyan Charlotte E. , Barker Christopher A. , Brady Mary Susan , Coit Daniel G. , Rosen Neal , Chapman Paul B. , Busam Klaus J. , Solit David B. , Panageas Katherine S. , Wolchok Jedd D. , Schultz Nikolaus
Published: April 2023

Supplementary Data Legends
Figure S3 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Authors: Shoushtari Alexander N. , Chatila Walid K. , Arora Arshi , Sanchez-Vega Francisco , Kantheti Havish S. , Rojas Zamalloa Jorge A. , Krieger Penina , Callahan Margaret K. , Betof Warner Allison , Postow Michael A. , Momtaz Parisa , Nair Suresh , Ariyan Charlotte E. , Barker Christopher A. , Brady Mary Susan , Coit Daniel G. , Rosen Neal , Chapman Paul B. , Busam Klaus J. , Solit David B. , Panageas Katherine S. , Wolchok Jedd D. , Schultz Nikolaus
Published: April 2023

Kaplan-Meier curves for overall survival. (A) PD-1 monotherapy by driver class. (B) nivolumab plus ipilimumab by driver class. (C) PD-1 monotherapy by primary site of melanoma. (D) nivolumab plus ipilimumab by primary site of melanoma.
Figure S2 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Authors: Shoushtari Alexander N. , Chatila Walid K. , Arora Arshi , Sanchez-Vega Francisco , Kantheti Havish S. , Rojas Zamalloa Jorge A. , Krieger Penina , Callahan Margaret K. , Betof Warner Allison , Postow Michael A. , Momtaz Parisa , Nair Suresh , Ariyan Charlotte E. , Barker Christopher A. , Brady Mary Susan , Coit Daniel G. , Rosen Neal , Chapman Paul B. , Busam Klaus J. , Solit David B. , Panageas Katherine S. , Wolchok Jedd D. , Schultz Nikolaus
Published: April 2023

(A) Oncoprint showing similar rates of driver alterations between cutaneous melanomas and melanomas of unknown primary. This suggests the vast majority of melanomas of unknown primary arose from regressed cutaneous sites. (B) Sequenced melanomas arising in females (N=244) have a lower median TMB than those arising in males (N=475; 15.7 vs 17.6 mut/Mb, p= 0.024). (C) The median fraction of alterations associated with an ultraviolet signature varies by MAPK Driver (p=9.6e-9). (D) The median fraction of alterations associated with an ultraviolet signature varies by primary site (p=3.9e-10).
Figure S1 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Authors: Shoushtari Alexander N. , Chatila Walid K. , Arora Arshi , Sanchez-Vega Francisco , Kantheti Havish S. , Rojas Zamalloa Jorge A. , Krieger Penina , Callahan Margaret K. , Betof Warner Allison , Postow Michael A. , Momtaz Parisa , Nair Suresh , Ariyan Charlotte E. , Barker Christopher A. , Brady Mary Susan , Coit Daniel G. , Rosen Neal , Chapman Paul B. , Busam Klaus J. , Solit David B. , Panageas Katherine S. , Wolchok Jedd D. , Schultz Nikolaus
Published: April 2023

CONSORT diagram of samples that underwent MSK-IMPACT sequencing and analyzed for clinical outcomes with frontline PD-1 based therapy.
Supp Figure 3 from Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET
Authors: Garcia-Moure Marc , Gonzalez-Huarriz Marisol , Labiano Sara , Guruceaga Elizabeth , Bandres Eva , Zalacain Marta , Marrodan Lucia , de Andrea Carlos , Villalba Maria , Martinez-Velez Naiara , Laspidea Virginia , Puigdelloses Montse , Gallego Perez-Larraya Jaime , Iñigo-Marco Ignacio , Stripecke Renata , Chan Jennifer A. , Raabe Eric H. , Kool Marcel , Gomez-Manzano Candelaria , Fueyo Juan , Patiño-García Ana , Alonso Marta M.
Published: April 2023

Supp Figure 3 Therapeutic effect of Delta-24-RGD in mice bearing PNET-like tumors.
Supp Figure 2 from Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET
Authors: Garcia-Moure Marc , Gonzalez-Huarriz Marisol , Labiano Sara , Guruceaga Elizabeth , Bandres Eva , Zalacain Marta , Marrodan Lucia , de Andrea Carlos , Villalba Maria , Martinez-Velez Naiara , Laspidea Virginia , Puigdelloses Montse , Gallego Perez-Larraya Jaime , Iñigo-Marco Ignacio , Stripecke Renata , Chan Jennifer A. , Raabe Eric H. , Kool Marcel , Gomez-Manzano Candelaria , Fueyo Juan , Patiño-García Ana , Alonso Marta M.
Published: April 2023

Supp Figure 2 Replication and cytolytic activity of Delta24-RGD in AT/RT, PNET, and PNET-like cell cultures.
Supp Figure 1 from Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET
Authors: Garcia-Moure Marc , Gonzalez-Huarriz Marisol , Labiano Sara , Guruceaga Elizabeth , Bandres Eva , Zalacain Marta , Marrodan Lucia , de Andrea Carlos , Villalba Maria , Martinez-Velez Naiara , Laspidea Virginia , Puigdelloses Montse , Gallego Perez-Larraya Jaime , Iñigo-Marco Ignacio , Stripecke Renata , Chan Jennifer A. , Raabe Eric H. , Kool Marcel , Gomez-Manzano Candelaria , Fueyo Juan , Patiño-García Ana , Alonso Marta M.
Published: April 2023

Supp Figure 1 Infectivity of Delta24-RGD in PNET-like cell cultures.
Supplementary Data from IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Authors: Thibodeaux Suzanne R. , Barnett Brian B. , Pandeswara Srilakshmi , Wall Shawna R. , Hurez Vincent , Dao Vinh , Sun Lishi , Daniel Benjamin J. , Brumlik Michael J. , Drerup Justin , Padrón Álvaro , Whiteside Teresa , Kryczek Ilona , Zou Weiping , Curiel Tyler J.
Published: April 2023

Fig. S9 IFN-α plus DD activates CD8+ T cell-mediated anti-tumor immunity.
Supplementary Data from IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Authors: Thibodeaux Suzanne R. , Barnett Brian B. , Pandeswara Srilakshmi , Wall Shawna R. , Hurez Vincent , Dao Vinh , Sun Lishi , Daniel Benjamin J. , Brumlik Michael J. , Drerup Justin , Padrón Álvaro , Whiteside Teresa , Kryczek Ilona , Zou Weiping , Curiel Tyler J.
Published: April 2023

Fig. S10 IFN-α plus DD minimally affects CD4+ T cell-mediated anti-tumor immunity.
Table S2 from HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor
Authors: Hemming Matthew L. , Coy Shannon , Lin Jia-Ren , Andersen Jessica L. , Przybyl Joanna , Mazzola Emanuele , Abdelhamid Ahmed Amr H. , van de Rijn Matt , Sorger Peter K. , Armstrong Scott A. , Demetri George D. , Santagata Sandro
Published: April 2023

CyCIF Antibodies
Table S1 from HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor
Authors: Hemming Matthew L. , Coy Shannon , Lin Jia-Ren , Andersen Jessica L. , Przybyl Joanna , Mazzola Emanuele , Abdelhamid Ahmed Amr H. , van de Rijn Matt , Sorger Peter K. , Armstrong Scott A. , Demetri George D. , Santagata Sandro
Published: April 2023

GIST RNA-seq Cohort
Supplementary Data from HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor
Authors: Hemming Matthew L. , Coy Shannon , Lin Jia-Ren , Andersen Jessica L. , Przybyl Joanna , Mazzola Emanuele , Abdelhamid Ahmed Amr H. , van de Rijn Matt , Sorger Peter K. , Armstrong Scott A. , Demetri George D. , Santagata Sandro
Published: April 2023

Supplementary figures and legends
Supplementary Figure 4S from Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer
Authors: Floberg John M. , Zhang Jin , Muhammad Naoshad , DeWees Todd A. , Inkman Matthew , Chen Kevin , Lin Alexander J. , Rashmi Ramachandran , Jayachandran Kay , Edelson Brian T. , Siegel Barry A. , Dehdashti Farrokh , Grigsby Perry W. , Markovina Stephanie , Schwarz Julie K.
Published: April 2023

Tissue microarray staining for CD163, a marker for M2 polarized macrophages.
Supplementary Figure 1 from A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Sarker Debashis , Dawson Nancy A. , Aparicio Ana M. , Dorff Tanya B. , Pantuck Allan J. , Vaishampayan Ulka N. , Henson Lynn , Vasist Lakshmi , Roy-Ghanta Sumita , Gorczyca Michele , York Whitney , Ganji Gopinath , Tolson Jerry , de Bono Johann S.
Published: April 2023

B: The dashed line represents 5 CTCs/7.5 mL. C: White circles indicate the location of the lymph node lesion with documented PR, demonstrating a 46% reduction in size from baseline. CT, computerized tomography; CTC, circulating tumor cells; PR, partial response; PSA, prostate-specific antigen.
Supplementary Figure 3S from Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer
Authors: Floberg John M. , Zhang Jin , Muhammad Naoshad , DeWees Todd A. , Inkman Matthew , Chen Kevin , Lin Alexander J. , Rashmi Ramachandran , Jayachandran Kay , Edelson Brian T. , Siegel Barry A. , Dehdashti Farrokh , Grigsby Perry W. , Markovina Stephanie , Schwarz Julie K.
Published: April 2023

Prognostic significance of SUVmax for local (cervix) recurrence (A) and any pelvic recurrence (B).
Figure S3 from Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer
Authors: Vathiotis Ioannis A. , Moutafi Myrto K. , Divakar Prajan , Aung Thazin Nwe , Qing Tao , Fernandez Aileen , Yaghoobi Vesal , El-Abed Sarra , Wang Yingbo , Guillaume Sebastien , Nuciforo Paolo , Huober Jens , Di Cosimo Serena , Kim Sung-Bae , Harbeck Nadia , Gomez Henry , Shafi Saba , Syrigos Konstantinos N. , Fountzilas George , Sotiriou Christos , Pusztai Lajos , Warren Sarah , Rimm David L.
Published: April 2023

Unsupervised hierarchical cluster analysis.
Figure S4 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Authors: Louveau Baptiste , Resche-Rigon Matthieu , Lesimple Thierry , Da Meda Laetitia , Pracht Marc , Baroudjian Barouyr , Delyon Julie , Amini-Adle Mona , Dutriaux Caroline , Reger de Moura Coralie , Sadoux Aurélie , Jouenne Fanélie , Ghrieb Zineb , Vilquin Paul , Bouton Didier , Tibi Annick , Huguet Samuel , Rezai Keyvan , Battistella Maxime , Mourah Samia , Lebbe Céleste
Published: April 2023

Figure S4. Differential gene expression analysis in responders vs nonresponders conducted on baseline samples. Three hundred fifty-eight genes were screened. Genes with FDR P-value <0.05 are labeled and in blue.
Supplementary Figure 2 from Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Authors: Johnson Melissa , El-Khoueiry Anthony , Hafez Navid , Lakhani Nehal , Mamdani Hirva , Rodon Jordi , Sanborn Rachel E. , Garcia-Corbacho Javier , Boni Valentina , Stroh Mark , Hannah Alison L. , Wang Song , Castro Henry , Spira Alexander
Published: April 2023

Patient Cases
Supplementary Tables from Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies
Authors: Lee Jaewon J. , Bernard Vincent , Semaan Alexander , Monberg Maria E. , Huang Jonathan , Stephens Bret M. , Lin Daniel , Rajapakshe Kimal I. , Weston Brian R. , Bhutani Manoop S. , Haymaker Cara L. , Bernatchez Chantale , Taniguchi Cullen M. , Maitra Anirban , Guerrero Paola A.
Published: April 2023

Tables
Supplementary Figure 5 from Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies
Authors: Lee Jaewon J. , Bernard Vincent , Semaan Alexander , Monberg Maria E. , Huang Jonathan , Stephens Bret M. , Lin Daniel , Rajapakshe Kimal I. , Weston Brian R. , Bhutani Manoop S. , Haymaker Cara L. , Bernatchez Chantale , Taniguchi Cullen M. , Maitra Anirban , Guerrero Paola A.
Published: April 2023

Figure
Supplementary Data from Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia
Authors: Dumas Pierre-Yves , Villacreces Arnaud , Guitart Amélie V. , El-habhab Ali , Massara Layal , Mansier Olivier , Bidet Audrey , Martineau Delphine , Fernandez Solene , Leguay Thibaut , Pigneux Arnaud , Vigon Isabelle , Pasquet Jean-Max , Desplat Vanessa
Published: April 2023

SUPPLEMENTARY DATA
Supplementary Data from SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma
Authors: Jatiani Shashidhar S. , Christie Stephanie , Leshchenko Violetta V. , Jain Rinku , Kapoor Abhijeet , Bisignano Paola , Lee Clement , Kaniskan H. Ümit , Edwards Donna , Meng Fanye , Laganà Alessandro , Youssef Youssef , Wiestner Adrian , Alinari Lapo , Jin Jian , Filizola Marta , Aggarwal Aneel K. , Parekh Samir
Published: April 2023

Supplemental Figures, Tables, Methods and References
Supplementary Data from Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
Authors: Kim Seung Tae , Smith Simon A. , Mortimer Peter , Loembé Arsene-Bienvenu , Cho Heejin , Kim Kyoung-Mee , Smith Claire , Willis Sophie , Irurzun-Arana Itziar , Berges Alienor , Hong Jung Yong , Park Se Hoon , Park Joon Oh , Park Young Suk , Lim Ho Yeong , Kang Won Ki , Kozarewa Iwanka , Pierce Andrew J. , Dean Emma , Lee Jeeyun
Published: April 2023

Supplementary Table 1. Treatment Outcomes for individual trial participants and dose cohort (N=57)
Table S5 from The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients
Authors: Zheng Bo , Liu Xiao-Long , Fan Rong , Bai Jian , Wen Hao , Du Lu-Tao , Jiang Guo-Qing , Wang Chun-Ying , Fan Xiao-Tang , Ye Yi-Nong , Qian Yun-Song , Wang Ying-Chao , Liu Gao-Jing , Deng Guo-Hong , Shen Feng , Hu He-Ping , Wang Hui , Zhang Qing-Zheng , Ru Lan-Lan , Zhang Jing , Gao Yan-Hang , Xia Jie , Yan Hua-Dong , Liang Min-Feng , Yu Yan-Long , Sun Fu-Ming , Gao Yu-Jing , Sun Jian , Zhong Chun-Xiu , Wang Yin , Kong Fei , Chen Jin-Ming , Zheng Dan , Yang Yuan , Wang Chuan-Xin , Wu Lin , Hou Jin-Lin , Liu Jing-Feng , Wang Hong-Yang , Chen Lei
Published: April 2023

Table S5
Supplementary Data from Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance
Authors: Beck Lir , Harel Michal , Yu Shun , Markovits Ettai , Boursi Ben , Markel Gal , Geiger Tamar
Published: April 2023

Supplementary Figures 1-7
Supplemental Figure 3 from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
Authors: Chang Jason C. , Offin Michael , Falcon Christina , Brown David , Houck-Loomis Brian R. , Meng Fanli , Rudneva Vasilisa A. , Won Helen H. , Amir Sharon , Montecalvo Joseph , Desmeules Patrice , Kadota Kyuichi , Adusumilli Prasad S. , Rusch Valerie W. , Teed Sarah , Sabari Joshua K. , Benayed Ryma , Nafa Khedoudja , Borsu Laetitia , Li Bob T. , Schram Alison M. , Arcila Maria E. , Travis William D. , Ladanyi Marc , Drilon Alexander , Rekhtman Natasha
Published: April 2023

Supplemental Figure 3. Comparison of overall and recurrence-free survival in TP53-wild type and TP53-mutant IMAs
Supplemental Figure 1 from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
Authors: Chang Jason C. , Offin Michael , Falcon Christina , Brown David , Houck-Loomis Brian R. , Meng Fanli , Rudneva Vasilisa A. , Won Helen H. , Amir Sharon , Montecalvo Joseph , Desmeules Patrice , Kadota Kyuichi , Adusumilli Prasad S. , Rusch Valerie W. , Teed Sarah , Sabari Joshua K. , Benayed Ryma , Nafa Khedoudja , Borsu Laetitia , Li Bob T. , Schram Alison M. , Arcila Maria E. , Travis William D. , Ladanyi Marc , Drilon Alexander , Rekhtman Natasha
Published: April 2023

Supplemental Figure 1. Consort diagram summarizing the molecular workflow of cases.
Table S9 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

Table S9. Differential gene analysis of LXH254 sensitive and insensitive cells lines
Supplementary Table S1 from Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma
Authors: Zengin Zeynep B. , Weipert Caroline , Salgia Nicholas J. , Dizman Nazli , Hsu Joann , Meza Luis , Chehrazi-Raffle Alexander , Muddasani Ramya , Salgia Sabrina , Malhotra Jasnoor , Chawla Neal , Philip Errol J. , Kiedrowski Lesli , Maughan Benjamin L. , Rathi Nityam , Goel Divyam , Choueiri Toni K. , Agarwal Neeraj , Pal Sumanta K.
Published: April 2023

Variant allele frequency of the alterations listed in Figure 2
Table S7 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

In vivo anti-tumor effects of LXH254 and Trametinib
Table S6 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

Proliferation and p-ERK IC50 results in RAS-mutant cells expressing only one RAF paralog
Supplementary Data from Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer
Authors: Kazi Aslamuzzaman , Chen Liwei , Xiang Shengyan , Vangipurapu Rajanikanth , Yang Hua , Beato Francisca , Fang Bin , Williams Terence M. , Husain Kazim , Underwood Patrick , Fleming Jason B. , Malafa Mokenge , Welsh Eric A. , Koomen John , Trevino José , Sebti Saïd M.
Published: April 2023

Supplementary Figures Legend
Table S4 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

Proliferation IC50 values for various cell lines and cell line derivatives
Supplementary Legend from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

Supplementary Legend
Supplementary Data from A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer
Authors: Garon Edward B. , Spira Alexander I. , Johnson Melissa , Bazhenova Lyudmila , Leach Joseph , Cummings Amy L. , Candia Albert , Coffman Robert L. , Janatpour Mary J. , Janssen Robert , Gamelin Erick , Chow Laura Q.M.
Published: April 2023

Supplement
Figure S3 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

Supplementary Figure 3. (A) Shown are western blots using antibodies directed against T202/Y204 phosphorylated ERK1/2 following incubation with a range of concentrations of LXH254 over a 4 - 72 hour period. Which individual RAF protein is not expressed in each HCT 116 variant is indicated above the relevant panels. (B) Shown are western blots using Abs directed against the indicated proteins in either whole cell lysates (WCL) or material immuno-precipitated from cell lysates using Abs directed against ARAF (ARAF IP) or BRAF (BRAF IP). Lysates were generated from either parental MIA PaCa-2 cells or a MIA PaCa-2 variant lacking expression of CRAF. (C) Recombinant MEK1 can be phosphorylated by immuno-precipitates from both LXH254 treated and untreated MIA PaCa-2 and MEL-JUSO cells using an anti-body directed against ARAF contains MEK1 kinase activity. Proteins detected in either whole cell lysates (WCL) or ARAF-Ab immuno-precipitates (IP:ARAF) are indicated on the right. (D) IP-kinase activity on recombinant MEK1 in immuno-precipitates from HEK293 cells expressing FLAG-tagged ARAF using Abs directed against FLAG requires ATP and occurs on both wild type (WT) and kinase-dead (K97M) MEK1. (E) Shown are western blots using antibodies directed against T202/Y204 phosphorylated ERK1/2 following incubation with a range of concentrations of LXH254 over a 4-72 hour period. The individual RAF protein expressed in each HCT 116 variant is indicated above the relevant panels. (F) Shown are western blots of phosphorylated MEK1/2 (S218/S221) and ERK1/2 (T202/Y204) following a 4 hr. incubation with a range of LXH254 concentrations in the RAS/RAF wild type cell line PC-9.
Supplementary Tables from Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4
Authors: Krijgsman Oscar , Kemper Kristel , Boshuizen Julia , Vredevoogd David W. , Rozeman Elisa A. , Ibanez Molero Sofia , de Bruijn Beaunelle , Cornelissen-Steijger Paulien , Shahrabi Aida , Del Castillo Velasco-Herrera Martin , Song Ji-Ying , Ligtenberg Maarten A. , Kluin Roelof J.C. , Kuilman Thomas , Ross-Macdonald Petra , Haanen John B.A.G. , Adams David J. , Blank Christian U. , Peeper Daniel S.
Published: April 2023

Supplementary Tables
Figure S1 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

Supplementary Figure 1. Shown in (A) are the IC50 values for the inhibition of proliferation for BRAF ( ), KRAS ( ), and NRAS ( ) mutant as well as "WT" ( ) cell lines. Below the graph Fischer's exact test using 1, 2, and 2.5ï�­M sensitivity cutoffs are provided. (B) Comparison of cell line sensitivities for LXH254 and RAF709. LXH254 values are provided in this manuscript (Sup. Table 3) and RAF709 values obtained from (25). (C) mRNA expression (RNASeq, https://portals.broadinstitute.org/ccle/data) for cell lines presented in (A) with the 2.0ï�­M LXH254 sensitivity threshold delineated. (D) ARAF mRNA expression in KRAS mutant and wild type cells from TCGA Pan-cancer Atlas Project (47), using the cBIO cancer genomics portal (https://www.cbioportal.org/, (1,2))
Supplementary Data for Smith et al SPARTAN AR Aberrations from Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease
Authors: Smith Matthew R. , Thomas Shibu , Gormley Michael , Chowdhury Simon , Olmos David , Oudard Stéphane , Feng Felix Y. , Rajpurohit Yashoda , Urtishak Karen , Ricci Deborah S. , Rooney Brendan , Lopez-Gitlitz Angela , Yu Margaret , Wyatt Alexander W. , Li Mark , Attard Gerhardt , Small Eric J.
Published: April 2023

Supplementary Data for Smith et al SPARTAN AR Aberrations
Figure S1 from Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma
Authors: Andrews David W. , Judy Kevin D. , Scott Charles B. , Garcia Samantha , Harshyne Larry A. , Kenyon Lawrence , Talekar Kiran , Flanders Adam , Atsina Kofi-Buaku , Kim Lyndon , Martinez Nina , Shi Wenyin , Werner-Wasik Maria , Liu Haisong , Prosniak Mikhail , Curtis Mark , Kean Rhonda , Ye Donald Y. , Bongiorno Emily , Sauma Sami , Exley Mark A. , Pigott Kara , Hooper D. Craig
Published: April 2023

Pan-Cancer Immunity Panel for advanced analysis of T cell activation scores
Supplementary Figure S4 from Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Authors: Hunter Anthony M. , Newman Hannah , Dezern Amy E. , Steensma David P. , Niyongere Sandrine , Roboz Gail J. , Mo Qianxing , Chan Onyee , Gerds Aaron , Sallman David A. , Dominguez-Viqueira William , Letson Christopher , Balasis Maria E. , Ball Markus , Kruer Traci , Zhang Hailing , Lancet Jeffrey E. , List Alan F. , Sekeres Mikkael A. , Komrokji Rami S. , Padron Eric
Published: April 2023

Supplementary Figure S4 compares baseline cytokine levels between responding and non-responding patients.
Supplementary Data from Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
Authors: Chua Khi Pin , Teng Yvonne H.F. , Tan Aaron C. , Takano Angela , Alvarez Jacob J.S. , Nahar Rahul , Rohatgi Neha , Lai Gillianne G.Y. , Aung Zaw Win , Yeong Joe P.S. , Lim Kiat Hon , Naeini Marjan Mojtabavi , Kassam Irfahan , Jain Amit , Tan Wan Ling , Gogna Apoorva , Too Chow Wei , Kanesvaran Ravindran , Ng Quan Sing , Ang Mei Kim , Rajasekaran Tanujaa , Anantham Devanand , Phua Ghee Chee , Tan Bien Soo , Lee Yin Yeng , Wang Lanying , Teo Audrey S.M. , Khng Alexis Jiaying , Lim Ming Jie , Suteja Lisda , Toh Chee Keong , Lim Wan-Teck , Iyer N. Gopalakrishna , Tam Wai Leong , Tan Eng-Huat , Zhai Weiwei , Hillmer Axel M. , Skanderup Anders J. , Tan Daniel S.W.
Published: April 2023

Supplementary Data from Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
Figure S2 from Regulation of OATP1B1 Function by Tyrosine Kinase–mediated Phosphorylation
Authors: Hayden Elizabeth R. , Chen Mingqing , Pasquariello Kyle Z. , Gibson Alice A. , Petti James J. , Shen Shichen , Qu Jun , Ong Su Sien , Chen Taosheng , Jin Yan , Uddin Muhammad Erfan , Huang Kevin M. , Paz Aviv , Sparreboom Alex , Hu Shuiying , Sprowl Jason A.
Published: April 2023

Percent of total tyrosine-phosphorylated spectral counts for all OATP1B1 tyrosine residues after exposure to DMSO (vehicle) or nilotinib (10 μM). Three concentrated OATP1B1 protein extracts were purified by immunoprecipitation and analyzed by LC-MS analysis, per treatment group. *denotes P < 0.05 vs vehicle or wild-type and all values represent mean {plus minus} SEM. Data is represented by 3 independent experiments.
Figure S1 from Regulation of OATP1B1 Function by Tyrosine Kinase–mediated Phosphorylation
Authors: Hayden Elizabeth R. , Chen Mingqing , Pasquariello Kyle Z. , Gibson Alice A. , Petti James J. , Shen Shichen , Qu Jun , Ong Su Sien , Chen Taosheng , Jin Yan , Uddin Muhammad Erfan , Huang Kevin M. , Paz Aviv , Sparreboom Alex , Hu Shuiying , Sprowl Jason A.
Published: April 2023

Influence of TKIs on OATP1B1-dependent uptake or substrate disposition. (A) Uptake of 3H-EβG (2 µM, 2 min) in OATP1B1 overexpressing HEK293 cells in the presence or absence of select individual FDA approved TKIs (10 μM) identified as positive or negative OATP1B1 inhibitors, following pre-treatment with TKIs for 15 minutes (n=6) (A). Data are presented as a percent of OATP1B1 activity compared to treatment with DMSO (Vehicle). *denotes P < 0.05 vs vehicle and all values represent mean {plus minus} SEM and the experiment was repeated on two separate occasions. (B) Time dependent plasma concentration of methotrexate following injection (10 mg/kg, i.v.) in the presence or absence of a 30-minute pre-treatment with nilotinib (37.5 mg/kg, p.o.). *denotes P < 0.05 vs vehicle and all values represent mean {plus minus} SEM of three male mice.
Supplementary Table 4 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Hajda Jacek , Leuchs Barbara , Angelova Assia L. , Frehtman Veronika , Rommelaere Jean , Mertens Mieke , Pilz Maximilian , Kieser Meinhard , Krebs Ottheinz , Dahm Michael , Huber Bernard , Engeland Christine E. , Mavratzas Athanasios , Hohmann Nicolas , Schreiber Jutta , Jäger Dirk , Halama Niels , Sedlaczek Oliver , Gaida Matthias M. , Daniel Volker , Springfeld Christoph , Ungerechts Guy
Published: April 2023

Supplementary Table 4
Supplementary Table 3 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Hajda Jacek , Leuchs Barbara , Angelova Assia L. , Frehtman Veronika , Rommelaere Jean , Mertens Mieke , Pilz Maximilian , Kieser Meinhard , Krebs Ottheinz , Dahm Michael , Huber Bernard , Engeland Christine E. , Mavratzas Athanasios , Hohmann Nicolas , Schreiber Jutta , Jäger Dirk , Halama Niels , Sedlaczek Oliver , Gaida Matthias M. , Daniel Volker , Springfeld Christoph , Ungerechts Guy
Published: April 2023

Supplementary Table 3
Supplementary Table 1 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Hajda Jacek , Leuchs Barbara , Angelova Assia L. , Frehtman Veronika , Rommelaere Jean , Mertens Mieke , Pilz Maximilian , Kieser Meinhard , Krebs Ottheinz , Dahm Michael , Huber Bernard , Engeland Christine E. , Mavratzas Athanasios , Hohmann Nicolas , Schreiber Jutta , Jäger Dirk , Halama Niels , Sedlaczek Oliver , Gaida Matthias M. , Daniel Volker , Springfeld Christoph , Ungerechts Guy
Published: April 2023

Supplementary Table 1
Supplementary Figure 3 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Hajda Jacek , Leuchs Barbara , Angelova Assia L. , Frehtman Veronika , Rommelaere Jean , Mertens Mieke , Pilz Maximilian , Kieser Meinhard , Krebs Ottheinz , Dahm Michael , Huber Bernard , Engeland Christine E. , Mavratzas Athanasios , Hohmann Nicolas , Schreiber Jutta , Jäger Dirk , Halama Niels , Sedlaczek Oliver , Gaida Matthias M. , Daniel Volker , Springfeld Christoph , Ungerechts Guy
Published: April 2023

Virus shedding in feces
Figure S3 from Sulindac, a Nonselective NSAID, Reduces Breast Density in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors
Authors: Thompson Patricia A. , Huang Chuan , Yang Jie , Wertheim Betsy C. , Roe Denise , Zhang Xiaoyue , Ding Jie , Chalasani Pavani , Preece Christina , Martinez Jessica , Chow H.-H. Sherry , Stopeck Alison T.
Published: April 2023

Spaghetti plots of mean arterial pressure (MAP) from clinical blood pressure measurements at three time points by study group.
Supplementary Data from Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type
Authors: Konuma Takaaki , Kanda Junya , Kuwatsuka Yachiyo , Yanada Masamitsu , Kondo Tadakazu , Hirabayashi Shigeki , Kako Shinichi , Akahoshi Yu , Uchida Naoyuki , Doki Noriko , Ozawa Yukiyasu , Tanaka Masatsugu , Eto Tetsuya , Sawa Masashi , Yoshioka Satoshi , Kimura Takafumi , Kanda Yoshinobu , Fukuda Takahiro , Atsuta Yoshiko , Kimura Fumihiko
Published: April 2023

Supplementary Data
Supplemental Tables 1-4 from Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study
Authors: de Clercq Nicolien C. , van den Ende Tom , Prodan Andrei , Hemke Robert , Davids Mark , Pedersen Helle K. , Nielsen Henrik B. , Groen A.K. , de Vos Willem M. , van Laarhoven Hanneke W.M. , Nieuwdorp Max
Published: April 2023

Supplemental Tables 1-4
Supplemental Materials from Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study
Authors: de Clercq Nicolien C. , van den Ende Tom , Prodan Andrei , Hemke Robert , Davids Mark , Pedersen Helle K. , Nielsen Henrik B. , Groen A.K. , de Vos Willem M. , van Laarhoven Hanneke W.M. , Nieuwdorp Max
Published: April 2023

Supplemental Materials
Figure S5. from Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study
Authors: de Clercq Nicolien C. , van den Ende Tom , Prodan Andrei , Hemke Robert , Davids Mark , Pedersen Helle K. , Nielsen Henrik B. , Groen A.K. , de Vos Willem M. , van Laarhoven Hanneke W.M. , Nieuwdorp Max
Published: April 2023

Alpha and beta-diversity by response
Figure S4. from Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study
Authors: de Clercq Nicolien C. , van den Ende Tom , Prodan Andrei , Hemke Robert , Davids Mark , Pedersen Helle K. , Nielsen Henrik B. , Groen A.K. , de Vos Willem M. , van Laarhoven Hanneke W.M. , Nieuwdorp Max
Published: April 2023

Shannon and species richness by FMT-type
Figure S11. from Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study
Authors: de Clercq Nicolien C. , van den Ende Tom , Prodan Andrei , Hemke Robert , Davids Mark , Pedersen Helle K. , Nielsen Henrik B. , Groen A.K. , de Vos Willem M. , van Laarhoven Hanneke W.M. , Nieuwdorp Max
Published: April 2023

Top 15 metabolites week 12
Figure S1. from Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study
Authors: de Clercq Nicolien C. , van den Ende Tom , Prodan Andrei , Hemke Robert , Davids Mark , Pedersen Helle K. , Nielsen Henrik B. , Groen A.K. , de Vos Willem M. , van Laarhoven Hanneke W.M. , Nieuwdorp Max
Published: April 2023

Study design
Supplementary Table 3 from Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
Authors: Lei Ming , Siemers Nathan O. , Pandya Dimple , Chang Han , Sanchez Teresa , Harbison Christopher , Szabo Peter M. , Janjigian Yelena , Ott Patrick A. , Sharma Padmanee , Bendell Johanna , Evans Thomas R. Jeffry , de Braud Filippo , Chau Ian , Boyd Zachary
Published: April 2023

Gene expression levels by cohort
Supplementary Table 2 from Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
Authors: Lei Ming , Siemers Nathan O. , Pandya Dimple , Chang Han , Sanchez Teresa , Harbison Christopher , Szabo Peter M. , Janjigian Yelena , Ott Patrick A. , Sharma Padmanee , Bendell Johanna , Evans Thomas R. Jeffry , de Braud Filippo , Chau Ian , Boyd Zachary
Published: April 2023

Corresponding % TC and CPS with response and OS
Figure.S3 from Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma
Authors: Lone Waseem , Bouska Alyssa , Sharma Sunandini , Amador Catalina , Saumyaranjan Mallick , Herek Tyler A. , Heavican Tayla B. , Yu Jiayu , Lim Soon Thye , Ong Choon Kiat , Slack Graham W. , Savage Kerry J. , Rosenwald Andreas , Ott German , Cook James R. , Feldman Andrew L. , Rimsza Lisa M. , McKeithan Timothy W. , Greiner Timothy C. , Weisenburger Dennis D. , Melle Federica , Motta Giovanna , Pileri Stefano , Vose Julie M. , Chan Wing C. , Iqbal Javeed
Published: April 2023

Figure S3: Identification of unique miRNA signatures for TH subsets: Heatmap of differentially expressed miRNA (p<0.05; fold-change>2 fold) in polarized CD4+ T-cell subsets. Signatures were derived from the directly polarized TH cells (Donor B/C) and evaluated in the pre-IL2 stimulated TH effector cells (Donor A)
Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
Authors: Subbiah Vivek , Gainor Justin F. , Oxnard Geoffrey R. , Tan Daniel S.W. , Owen Dwight H. , Cho Byoung Chul , Loong Herbert H. , McCoach Caroline E. , Weiss Jared , Kim Yu Jung , Bazhenova Lyudmila , Park Keunchil , Daga Haruko , Besse Benjamin , Gautschi Oliver , Rolfo Christian , Zhu Edward Y. , Kherani Jennifer F. , Huang Xin , Kang Suhyun , Drilon Alexander
Published: April 2023

Tumor response of patients with RET fusion-positive NSCLC & measurable intracranial disease
Tables S3 from Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Authors: Ewing Ailith , Meynert Alison , Churchman Michael , Grimes Graeme R. , Hollis Robert L. , Herrington C. Simon , Rye Tzyvia , Bartos Clare , Croy Ian , Ferguson Michelle , Lennie Mairi , McGoldrick Trevor , McPhail Neil , Siddiqui Nadeem , Dowson Suzanne , Glasspool Rosalind , Mackean Melanie , Nussey Fiona , McDade Brian , Ennis Darren , McMahon Lynn , Matakidou Athena , Dougherty Brian , March Ruth , Barrett J. Carl , McNeish Iain A. , Biankin Andrew V. , Roxburgh Patricia , Gourley Charlie , Semple Colin A.
Published: April 2023

Supplementary tables 3a and 3b. Germline and somatic SNVs/indels at BRCA1/2.
Table S7 from Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Authors: Ewing Ailith , Meynert Alison , Churchman Michael , Grimes Graeme R. , Hollis Robert L. , Herrington C. Simon , Rye Tzyvia , Bartos Clare , Croy Ian , Ferguson Michelle , Lennie Mairi , McGoldrick Trevor , McPhail Neil , Siddiqui Nadeem , Dowson Suzanne , Glasspool Rosalind , Mackean Melanie , Nussey Fiona , McDade Brian , Ennis Darren , McMahon Lynn , Matakidou Athena , Dougherty Brian , March Ruth , Barrett J. Carl , McNeish Iain A. , Biankin Andrew V. , Roxburgh Patricia , Gourley Charlie , Semple Colin A.
Published: April 2023

SV loads in non-BRCA1/2 HR genes per sample by SV type
Supplementary Tables S1-S3 from FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions
Authors: Kim Janice , Bradford Diana , Larkins Erin , Pai-Scherf Lee H. , Chatterjee Somak , Mishra-Kalyani Pallavi S. , Wearne Emily , Helms Whitney S. , Ayyoub Amal , Bi Youwei , Sun Jielin , Charlab Rosane , Liu Jiang , Zhao Hong , Liang Dun , Ghosh Soma , Philip Reena , Pazdur Richard , Theoret Marc R. , Beaver Julia A. , Singh Harpreet
Published: April 2023

Supplementary Tables S1-S3
Supplementary Video S4 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
Authors: Xiao Lin , Somers Klaartje , Murray Jayne , Pandher Ruby , Karsa Mawar , Ronca Emma , Bongers Angelika , Terry Rachael , Ehteda Anahid , Gamble Laura D. , Issaeva Natalia , Leonova Katerina I. , O'Connor Aisling , Mayoh Chelsea , Venkat Pooja , Quek Hazel , Brand Jennifer , Kusuma Frances K. , Pettitt Jessica A. , Mosmann Erin , Kearns Adam , Eden Georgina , Alfred Stephanie , Allan Sophie , Zhai Lei , Kamili Alvin , Gifford Andrew J. , Carter Daniel R. , Henderson Michelle J. , Fletcher Jamie I. , Marshall Glenn , Johnstone Ricky W. , Cesare Anthony J. , Ziegler David S. , Gudkov Andrei V. , Gurova Katerina V. , Norris Murray D. , Haber Michelle
Published: April 2023

HT10806TG_Combination treatment
Table S1 from Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Authors: Ewing Ailith , Meynert Alison , Churchman Michael , Grimes Graeme R. , Hollis Robert L. , Herrington C. Simon , Rye Tzyvia , Bartos Clare , Croy Ian , Ferguson Michelle , Lennie Mairi , McGoldrick Trevor , McPhail Neil , Siddiqui Nadeem , Dowson Suzanne , Glasspool Rosalind , Mackean Melanie , Nussey Fiona , McDade Brian , Ennis Darren , McMahon Lynn , Matakidou Athena , Dougherty Brian , March Ruth , Barrett J. Carl , McNeish Iain A. , Biankin Andrew V. , Roxburgh Patricia , Gourley Charlie , Semple Colin A.
Published: April 2023

Number of samples with BRCA1/2 SVs
Supplementary Video S3 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
Authors: Xiao Lin , Somers Klaartje , Murray Jayne , Pandher Ruby , Karsa Mawar , Ronca Emma , Bongers Angelika , Terry Rachael , Ehteda Anahid , Gamble Laura D. , Issaeva Natalia , Leonova Katerina I. , O'Connor Aisling , Mayoh Chelsea , Venkat Pooja , Quek Hazel , Brand Jennifer , Kusuma Frances K. , Pettitt Jessica A. , Mosmann Erin , Kearns Adam , Eden Georgina , Alfred Stephanie , Allan Sophie , Zhai Lei , Kamili Alvin , Gifford Andrew J. , Carter Daniel R. , Henderson Michelle J. , Fletcher Jamie I. , Marshall Glenn , Johnstone Ricky W. , Cesare Anthony J. , Ziegler David S. , Gudkov Andrei V. , Gurova Katerina V. , Norris Murray D. , Haber Michelle
Published: April 2023

HT10806TG_Panobinostat treatment
Supplementary Information from Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Authors: Ewing Ailith , Meynert Alison , Churchman Michael , Grimes Graeme R. , Hollis Robert L. , Herrington C. Simon , Rye Tzyvia , Bartos Clare , Croy Ian , Ferguson Michelle , Lennie Mairi , McGoldrick Trevor , McPhail Neil , Siddiqui Nadeem , Dowson Suzanne , Glasspool Rosalind , Mackean Melanie , Nussey Fiona , McDade Brian , Ennis Darren , McMahon Lynn , Matakidou Athena , Dougherty Brian , March Ruth , Barrett J. Carl , McNeish Iain A. , Biankin Andrew V. , Roxburgh Patricia , Gourley Charlie , Semple Colin A.
Published: April 2023

Supplementary methods and supplementary figures